Pemphigus foliaceus (PF) and the endemic form Fogo Selvagem (FS) are mediated by pathogenic antibodies to the EC1-2 domains of desmoglein-1. There is a preclinical phase with antibodies to only EC5. Based on geographic clustering of cases, FS is thought to have an, as yet unidentified, environmental trigger. In this study we have searched for anti-desmoglein-1 antibodies in sera from parasitic (leishmaniasis, Chagas, and onchocerciasis), and infectious diseases (leprosy and South American (SA) blastomycosis), which are prevalent in the same geographic regions of Brazil as FS. A specific and sensitive desmoglein-1 ELISA detected antibodies in 34 of 41 onchocerciasis (83%), 38 of 88 leishmaniasis (43%), 18 of 31 Chagas disease (58%), 7 of 28 SA blastomycosis (25%), and 14 of 83 leprosy sera (17%). These sera recognized epitopes restricted to the EC5 domain. These findings identify several etiological factors for FS. It is hypothesized that a component of insect vector saliva, rather than the parasite itself may trigger an antibody response to EC-5. In persons with the known HLA susceptibility alleles and living in endemic areas, a response to the EC1-2 domains may subsequently develop by epitope spreading with associated clinical signs of FS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.0022-202X.2004.23438.x | DOI Listing |
Arch Dermatol Res
October 2024
Department of Pediatric Allergy- Immunology, Marmara University School of Medicine, Istanbul, Turkey.
Indian J Dermatol
June 2024
From the Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Indian Dermatol Online J
April 2024
Department of Biostatistics, AIIMS, New Delhi, India.
Background: Rituximab infusion and dexamethasone-cyclophosphamide pulse (DCP) are the two most popular regimens used in pemphigus vulgaris (PV) in India.
Objective: The present study compared the clinical efficacy of rituximab and DCP in Indian PV patients and their effects on serum Th1,2, and 17 cytokine levels.
Materials And Methods: A total of 37 patients received DCP (Group A, = 22) or rituximab (Group B, rheumatoid arthritis protocol ( = 15)) as per patients' preference.
Ann Dermatol Venereol
June 2024
Dermatology Department, Henri-Mondor Hospital AP-HP, Créteil, France; Université Paris Est Créteil EpidermE, Créteil, France; Competence Center for Autoimmune Bullous Diseases MALIBUL, Henri-Mondor Hospital AP-HP, Créteil, France. Electronic address:
Background: Following the RITUX 3 therapeutic trial, the French national diagnosis and care protocol (NDCP) for the treatment of pemphigus was updated in 2018. The updated protocol recommends initial treatment with rituximab (RTX) followed by maintenance therapy at 12 and 18 months, and potentially at 6 months where there are risk factors for early relapse. We evaluated these recommendations regarding the management of our own patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!